Metformin (Background drug)

DRUG3 trials

Sponsors

Sanofi

Conditions

Type 2 DiabetesType 2 Diabetes Mellitus

Phase 2

Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Combination Versus Insulin Glargine Alone on Top of Metformin in Type 2 Diabetic Patients

CompletedNCT01476475

SanofiType 2 Diabetes Mellitus

Start: 2011-11-30End: 2012-12-31Updated: 2017-02-10

Phase 3

Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients

CompletedNCT01768559

SanofiType 2 Diabetes

Start: 2013-01-31End: 2014-12-31Updated: 2017-01-04

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes

CompletedNCT02058160

SanofiType 2 Diabetes

Start: 2014-01-31End: 2015-07-31Updated: 2017-05-09

Related Papers

Efficacy and Safety of iGlarLixi, Fixed-Ratio Combination of Insulin Glargine and Lixisenatide, Compared with Basal-Bolus Regimen in Patients with Type 2 Diabetes: Propensity Score Matched Analysis.

2019-12-1717 citations

Glycaemic target attainment in people with Type 2 diabetes treated with insulin glargine/lixisenatide fixed-ratio combination: a post hoc analysis of the LixiLan-O and LixiLan-L trials.

2019-11-263 citations

Clinical Characteristics and Glycemic Outcomes of Patients with Type 2 Diabetes Requiring Maximum Dose Insulin Glargine/Lixisenatide Fixed-Ratio Combination or Insulin Glargine in the LixiLan-L Trial.

2019-07-292 citations

EFFICACY AND SAFETY OF IGLARLIXI IN HISPANICS AND NON-HISPANIC WHITES WITH TYPE 2 DIABETES.

2019-06-26

Post hoc efficacy and safety analysis of insulin glargine/lixisenatide fixed- ratio combination in North American patients compared with the rest of world

BMJ Open Diabetes Research & Care2019-03-013 citations

Impact of dose capping in insulin glargine/lixisenatide fixed-ratio combination trials in patients with type 2 diabetes.

2019-01-112 citations

Bedtime-to-Morning Glucose Difference and iGlarLixi in Type 2 Diabetes: Post Hoc Analysis of LixiLan-L.

2018-09-141 citations

A1C Target Attainment in Patients with T2D Receiving iGlarLixi Who Reach PPG and FPG Targets in the Lixilan-L Trial

Diabetes2018-06-222 citations

Relationship of Ethnicity to Clinical Outcomes in iGlarLixi-Treated Patients with Type 2 Diabetes

Diabetes2018-06-221 citations

Low incidence of gastrointestinal adverse events over time with a fixed‐ratio combination of insulin glargine and lixisenatide versus lixisenatide alone

Diabetes Obesity and Metabolism2018-06-2021 citations

iGlarLixi Reduces Glycated Hemoglobin to a Greater Extent Than Basal Insulin Regardless of Levels at Screening: Post Hoc Analysis of LixiLan-L.

2017-11-168 citations

Consistent findings in glycaemic control, body weight and hypoglycaemia with <scp>iGlarLixi</scp> (insulin glargine/lixisenatide titratable fixed‐ratio combination) vs insulin glargine across baseline <scp>HbA1c</scp> , <scp>BMI</scp> and diabetes duration categories in the <scp>LixiLan‐L</scp> trial

Diabetes Obesity and Metabolism2017-04-0626 citations